EVALUATION OF THE EFFICACY OF THE ANGIOTENSIN RECEPTOR–NEPRILYSIN INHIBITOR (SACUBITRIL/VALSARTAN) IN PATIENTS WITH CHRONIC HEART FAILURE AND RENAL DYSFUNCTION.

Abstract

Chronic heart failure (CHF) is frequently accompanied by renal dysfunction, forming cardiorenal syndrome and significantly worsening prognosis. Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), has demonstrated superior outcomes compared with conventional renin–angiotensin system blockade; however, data in patients with impaired renal function remain limited. To evaluate the clinical efficacy, cardiac remodeling effects, and renal safety of sacubitril/valsartan in patients with chronic heart failure and renal dysfunction.

Identifiers

DOI

10.5281/zenodo.18432789

Citations and references